Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Wenzhou Medical University | OTHER |
Not provided
Not provided
Not provided
Not provided
Background: By the end of 2022, China had about 280 million people aged 60 and older, making up 19.8% of the population. This number is projected to exceed 300 million by the end of the 14th Five-Year Plan and 400 million by 2035, which would be over 30%. The 20th National Congress emphasized the need for a proactive strategy to tackle aging challenges. Approximately 6.04% of the elderly have dementia, with 3.94% having Alzheimer's disease. This totals around 15 million people with dementia. To address this, the China Cohort Consortium on Aging and Cognitive Impairment Development has been proposed to study health and cognitive changes in different age groups, aiming to support healthy aging policies. Methods: Participants from various age groups (children, youth, middle-aged, elderly) will be recruited from hospitals, schools, and communities using stratified sampling. They will undergo detailed medical examinations focusing on aging, cognitive impairments, and related diseases. A new database will track healthy aging and cognitive impairment development. Content: The study will involve comprehensive medical examinations, including physiological assessments, psychological evaluations, cognitive screenings, daily life assessments, imaging studies, and blood tests, to establish a detailed health and cognitive impairment database. The research will also investigate integrated intervention models in hospital, community, and home settings, develop remote medical management systems, and devise biomarker test kits for aging and cognitive impairments. Furthermore, it will concentrate on non-pharmacological interventions and artificial intelligence systems for the early detection, prevention, and treatment of aging-related conditions. Objectives: The China Cohort Consortium on Aging and Cognitive Impairment Development, commencing with the HAPCAD study, aims to monitor changes across various age groups, evaluate the impact of aging on health and cognitive function, and design targeted interventions. The objective is to enhance health management and services related to aging, establish effective strategies, develop therapeutic drugs, and promote healthy aging.
Research Objectives:
Establish detailed medical examinations for population cohorts across different age groups, including physiological checks, psychological assessments, cognitive function screenings, evaluations of daily life abilities, imaging, and blood tests, to build a comprehensive health and mental impairments database. Develop artificial intelligence systems for early warnings related to aging-related diseases and create prevention and treatment strategies. Focus on advancing health management, interventions, research, and services related to healthy aging and aging-related diseases, and develop effective intervention strategies and therapeutic drugs to promote healthy aging.
Research Content:
Research Methods and Technical Roadmap:
4.1. Genomics: Use the Illumina platform for whole-genome sequencing (WGS) to identify genetic variations and conduct genotype diversity, evolution analysis, and disease screening. Perform whole-genome bisulfite sequencing (WGBS) to study DNA methylation, which supports research on genome-wide methylation modifications relevant to aging and diseases.
4.2. Transcriptomics: Utilize the Illumina platform for next-generation sequencing to analyze coding and non-coding RNAs. Employ the 10x Chromium Single Cell Gene Expression Solution platform for single-cell gene expression profiling, enabling detailed analysis of cell populations and creating single-cell expression atlases.
4.3. Proteomics and Metabolomics: Study protein composition and activity patterns using proteomics and explore small molecule metabolites using metabolomics. Integrate data from both approaches to identify differential proteins and metabolites and describe molecular regulatory mechanisms.
Follow-Up and Tracking:
Track and follow up with enrolled participants.
Experimental Methods:
Employ traditional and advanced statistical methods, including t-tests, non-parametric tests, chi-square tests, logistic regression, Cox proportional hazards models, artificial neural networks, and Bayesian models. Analyze data to identify biomarkers for disease prediction, explore disease mechanisms, and guide treatment strategies. Utilize samples for scientific analysis, molecular experiments, and drug development.
Key Technologies and Descriptions:
Sample Processing: Use centrifuges, slicers, pipettes, and DNA/RNA extraction instruments. Following standardized procedures, store samples in low-temperature equipment, including refrigerators, freezers, and liquid nitrogen tanks.
Simoa Detection Technology:
Utilize Simoa for single-molecule detection with high sensitivity, using capture antibody binding sites on magnetic beads and detecting signals using CCD cameras. This technology allows for precise measurement of protein concentrations.
Annual Research Plan:
Recruit volunteers from hospitals of all age groups for comprehensive physical examinations, aiming to establish a detailed human growth and aging map.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Observation group | Establish a screening and long-term tracking cohort study related to healthy aging and the development of cognitive impairments to understand changes in physiological, psychological, mental, and daily living abilities across different age groups in humans. Analyze genetic factors, environmental influences, lifestyle, and their impacts on the occurrence and development of healthy aging, cognitive impairments, and other age-related diseases. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Assessing the prevalence of cognitive impairment in China based on MMSE, MoCA and CDR. | The statement involves evaluating the prevalence of cognitive impairment in China using three assessment tools: the Mini-Mental State Examination (MMSE), the Montreal Cognitive Assessment (MoCA), and the Clinical Dementia Rating (CDR). MMSE: This test has a maximum score of 30 points, with scores below 24 typically indicating cognitive impairment. MoCA: The MoCA also has a maximum score of 30 points, where a score of 26 or lower indicates cognitive impairment. CDR: The CDR uses a scale from 0 to 3, where 0 indicates no cognitive impairment, 0.5 suggests mild cognitive impairment, 1 denotes mild dementia, 2 indicates moderate dementia, and 3 reflects severe dementia. | through study completion, an average of 5 year. |
| Change in Alzheimer disease biomarkers over time | Aβ, t-tau and p-tau levels in pg/ml | through study completion, an average of 3 year. |
| Measure | Description | Time Frame |
|---|---|---|
| Changes of brain structure at different stage of cognitive impairment in Alzheimer disease in China. | Changes of structure of the whole brain, hippocampus other brain structures measured by MRI. | through study completion, an average of 5 year. |
| Changes of brain glucose metabolism at different stage of cognitive impairment in Alzheimer disease in China. |
| Measure | Description | Time Frame |
|---|---|---|
| Changes in Lifestyle factors over time: Smoking | Smoking: never/past/current | Measured at Baseline, year 1, year3, year 5, year 10 |
| Changes in Lifestyle factors over time: Alcohol Consumption | Alcohol: units/week |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
The study population is sourced from communities, hospitals, and healthy volunteers. There is no requirement for randomization of study subjects at enrollment. However, during further testing and analysis, one or more researchers select appropriate case samples for grouping and blinding assessors, and analysts is implemented to prevent bias.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Sipei Pan Dr. | Contact | 86+13758710622 | pansipei@wmu.edu.cn | |
| Qin-Fen Chen Dr. | Contact | 86+15167735852 | chenqinfen@wmu.edu.cn |
| Name | Affiliation | Role |
|---|---|---|
| Weihong Song Prof. | First Affiliated Hospital of Wenzhou Medical University | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| The First Affiliated Hospital of Wenzhou Medical University | Recruiting | Wenzhou | Zhejiang | 32500 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D060825 | Cognitive Dysfunction |
| D000544 | Alzheimer Disease |
| ID | Term |
|---|---|
| D003072 | Cognition Disorders |
| D019965 | Neurocognitive Disorders |
| D001523 | Mental Disorders |
| D003704 | Dementia |
Not provided
Not provided
Not provided
Not provided
Not provided
Blood (Serum, Plasma, Whole Blood, RNA, DNA) Urine Saliva CSF
Changes of glucose metabolism of the whole brain, hippocampus and other brain structures as measured by 18F-fluorodeoxyglucose (FDG)-positron emission tomography (PET). |
| through study completion, an average of 3 year. |
| Changes of brain amyloid deposition at different stage of cognitive impairment in Alzheimer disease in China. | Changes of amyloid deposition of the whole brain, hippocampus and other brain structures as measured by amyloid PET. | through study completion, an average of 3 year. |
| Changes of brain tau deposition at different stage of cognitive impairment in Alzheimer disease in China. | Changes of tau deposition of the whole brain, hippocampus and other brain structures as measured by tau PET. | through study completion, an average of 3 year. |
| Measured at Baseline, year 1, year3, year 5, year 10 |
| Changes in Lifestyle factors over time: drug abuse/misuse | Drug abuse/misuse: never/past/current | Measured at Baseline, year 1, year3, year 5, year 10 |
| Changes in Lifestyle factors over time: physical activity frequency | Physical activity: daily, 2-3 times/week, 2-3 times/month, a few times a year, not at all | Measured at Baseline, year 1, year3, year 5, year 10 |
| Changes in Lifestyle factors over time: Sleep, total over time, units on a scale | Sleep: Pittsburgh Sleep Quality Index | Measured at Baseline, year 1, year3, year 5, year 10 |
| Other neuro-imaging measure: Vascular Burden, over time, units on a scale | Vascular Burden: Counts of White Matter Lesions, infarcts, laciness, micro bleeds and superficial siderosis. | Measured at Baseline, year 1, year3, year 5, year 10 |
| Sociodemographic Factors | Date of Birth, Age, Ethnicity, Education, Marital Status, Handedness | Measured at Baseline |
| Family History of Alzheimer disease | Family history of Alzheimer disease in number of family members of first degree with history compatible with Alzheimer disease | Measured at Baseline |
| Medical History | Medical History: Yes/No for: Stroke, Diabetes (type 1 or 2), Hypertension, Hypercholesterolemia, Myocardial Infarction, Chronic Ischemic Heart Disease, Chronic Obstructive Pulmonary Disease, Asthma, Depression, Rheumatoid Arthritis, Any Cancer, Head Injury assessed with the Brain Injury Screening Questionnaire (BISQ), Mild Cognitive Impairment. | Measured at Baseline, year 1, year3, year 5, year 10 |
| Current Medication | Drug, treatment duration (<1year / 1-5years / >5years) | Measured at Baseline, year 1, year3, year 5, year 10 |
| Other clinical measure: Body Height | Body Height: without shoes, measured to the nearest cm | Measured at Baseline |
| Other clinical measure: Body Weight | Body Weight: measured to the nearest 0.1kg | Measured at Baseline, year 1, year3, year 5, year 10 |
| Other clinical measure: Hip-waist Circumference | Hip-waist Circumference: measured to nearest 0.1cm | Measured at Baseline, year 1, year3, year 5, year 10 |
| D001927 |
| Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D024801 | Tauopathies |
| D019636 | Neurodegenerative Diseases |